EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Synergistic Protection of Retinal Ganglion Cells (RGCs) by SARM1 Inactivation with CNTF in a Rodent Model of Nonarteritic Anterior Ischemic Optic Neuropathy

Yan Guo, Zara Mehrabian, Jeffrey Milbrandt, Aaron DiAntonio, Steven L Bernstein iD

Cells · 2024

DOI: 10.3390/cells13030202 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, 2024. Verfasst von Yan Guo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Ophthalmology and Visual Sciences, School of Medicine, University of Maryland, Baltimore, MD 21201, USA. Hauptthemen laut MEDLINE: Optic Neuropathy, Ischemic, Retinal Ganglion Cells. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NEI NIH HHS, NINDS NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We evaluated whether inhibiting sterile alpha and (Toll/interleukin receptor (TIR)) motif-containing 1 (SARM1) activity protects retinal ganglion cells (RGCs) following ischemic axonopathy (rodent nonarteritic anterior ischemic optic neuropathy: rNAION) by itself and combined with ciliary neurotrophic factor (CNTF). Genetically modified SARM1(−) rats were rNAION-induced in one eye and compared against equivalently induced wild-type animals of the same background. Optic nerve (ON) diameters were quantified using optical coherence tomography (SD-OCT). RGCs were quantified 30 d post-induction using retinal stereology for Brn3a(+) nuclei. ON sections were analyzed by TEM and immunohistochemistry. SARM1(−)(−) and WT animals were then bilaterally sequentially rNAION-induced. One eye received intravitreal vehicle injection following induction; the contralateral side received CNTF and was analyzed 30 d post-induction. Inhibiting SARM1 activity suppressed axonal collapse following ischemic axonopathy. SARM1(−) animals significantly reduced RGC loss, compared with WT animals (49.4 ± 6.8% RGC loss in SARM1(−) vs. 63.6 ± 3.2% sem RGC loss in WT; Mann–Whitney one-tailed U-test, (p = 0.049)). IVT-CNTF treatment vs. IVT-vehicle in SARM1(−) animals further reduced RGC loss by 24% at 30 d post-induction, but CNTF did not, by itself, improve long-term RGC survival in WT animals compared with vehicle (Mann–Whitney one-tailed t-test; p = 0.033). While inhibiting SARM1 activity is itself neuroprotective, combining SARM1 inhibition and CNTF treatment generated a long-term, synergistic neuroprotective effect in ischemic neuropathy. Combinatorial treatments for NAION utilizing independent neuroprotective mechanisms may thus provide a greater effect than individual treatment modalities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Optic Neuropathy, IschemicRetinal Ganglion CellsAnimalsRatsAnimals, WildCiliary Neurotrophic FactorRetinaRodentiaCytoskeletal ProteinsArmadillo Domain Proteins

Stichwörter der Autor:innen

axonopathyciliary neurotrophic factorischemianeuroprotectionnonarteritic anterior ischemic optic neuropathy (NAION)optic nerveretinal ganglion cellsrodentsterile alpha and (toll/interleukin receptor (TIR)) motif-containing 1 (SARM1)synergism

Substanzen

Ciliary Neurotrophic FactorSarm1 protein, ratCytoskeletal ProteinsArmadillo Domain Proteins

Autor:innen und Institutionen

  • Departments of Ophthalmology and Visual Sciences, School of Medicine, University of Maryland, Baltimore, MD 21201, USA.
  • Department of Genetics, Washington University School of Medicine, St. Louis, MO 63110, USA.
  • Needleman Center for Neurometabolism and Axonal Therapeutics, St. Louis, MO 63110, USA.
  • Department of Developmental Biology, Washington University School of Medicine, St. Louis, MO 63110, USA.
  • Anatomy and Neurobiology, School of Medicine, University of Maryland, Baltimore, MD 21201, USA.

ORCID-Profile: Steven L Bernstein

Förderung

  • NEI NIH HHS
  • NINDS NIH HHS
  • NIH HHS
  • NIH
  • Hillside Foundation

Zitieren

APA

Guo, Y., Mehrabian, Z., Milbrandt, J., DiAntonio, A., & Bernstein, S. L. (2024). Synergistic Protection of Retinal Ganglion Cells (RGCs) by SARM1 Inactivation with CNTF in a Rodent Model of Nonarteritic Anterior Ischemic Optic Neuropathy. Cells. https://doi.org/10.3390/cells13030202

Vancouver

Guo Y, Mehrabian Z, Milbrandt J, DiAntonio A, Bernstein SL. Synergistic Protection of Retinal Ganglion Cells (RGCs) by SARM1 Inactivation with CNTF in a Rodent Model of Nonarteritic Anterior Ischemic Optic Neuropathy. Cells. 2024. doi:10.3390/cells13030202

BibTeX
@article{Guo2024,
  author = {Guo, Yan and Mehrabian, Zara and Milbrandt, Jeffrey and DiAntonio, Aaron and Bernstein, Steven L},
  title = {Synergistic Protection of Retinal Ganglion Cells (RGCs) by SARM1 Inactivation with CNTF in a Rodent Model of Nonarteritic Anterior Ischemic Optic Neuropathy},
  journal = {Cells},
  year = {2024},
  doi = {10.3390/cells13030202}
}
Kostenlos starten →